371 related articles for article (PubMed ID: 9973012)
41. Impact of serum flecainide level on control of atrial fibrillation in a case treated with cardiac resynchronization therapy.
Doki K; Homma M; Kuga K; Kawano S; Aonuma K; Yamaguchi I; Kohda Y
J Clin Pharm Ther; 2007 Aug; 32(4):409-11. PubMed ID: 17635343
[TBL] [Abstract][Full Text] [Related]
42. Atrial fibrillatory frequency predicts atrial defibrillation threshold and early arrhythmia recurrence in patients undergoing internal cardioversion of persistent atrial fibrillation.
Bollmann A; Mende M; Neugebauer A; Pfeiffer D
Pacing Clin Electrophysiol; 2002 Aug; 25(8):1179-84. PubMed ID: 12358167
[TBL] [Abstract][Full Text] [Related]
43. A comparison of transvenous atrial defibrillation of acute and chronic atrial fibrillation and the effect of intravenous sotalol on human atrial defibrillation threshold.
Lau CP; Lok NS
Pacing Clin Electrophysiol; 1997 Oct; 20(10 Pt 1):2442-52. PubMed ID: 9358486
[TBL] [Abstract][Full Text] [Related]
44. Defibrillation efficacy and pain perception of two biphasic waveforms for internal cardioversion of atrial fibrillation.
Jung J; Hahn SJ; Heisel A; Buob A; Schubert BD; Siaplaouras S
J Cardiovasc Electrophysiol; 2003 Aug; 14(8):837-40. PubMed ID: 12890046
[TBL] [Abstract][Full Text] [Related]
45. The interaction of antiarrhythmic drugs and the energy for cardioversion of chronic atrial fibrillation.
Guarnieri T; Tomaselli G; Griffith LS; Brinker J
Pacing Clin Electrophysiol; 1991 Jun; 14(6):1007-12. PubMed ID: 1715060
[TBL] [Abstract][Full Text] [Related]
46. Incidence and modes of onset of early reinitiation of atrial fibrillation after successful internal cardioversion, and its prevention by intravenous sotalol.
Tse HF; Lau CP; Ayers GM
Heart; 1999 Sep; 82(3):319-24. PubMed ID: 10455082
[TBL] [Abstract][Full Text] [Related]
47. Randomised double blind trial of oral versus intravenous flecainide for the cardioversion of acute atrial fibrillation.
Alp NJ; Bell JA; Shahi M
Heart; 2000 Jul; 84(1):37-40. PubMed ID: 10862585
[TBL] [Abstract][Full Text] [Related]
48. Inhaled Oral Flecainide for Rapid Cardioversion of Atrial Fibrillation.
Kiani S
JACC Clin Electrophysiol; 2024 Jun; 10(6):1034-1036. PubMed ID: 38795097
[No Abstract] [Full Text] [Related]
49. Serial cardioversion by class IC Drugs during 4 months of persistent atrial fibrillation in the goat.
Eijsbouts S; Ausma J; Blaauw Y; Schotten U; Duytschaever M; Allessie MA
J Cardiovasc Electrophysiol; 2006 Jun; 17(6):648-54. PubMed ID: 16836716
[TBL] [Abstract][Full Text] [Related]
50. Does flecainide regain its antiarrhythmic activity after electrical cardioversion of persistent atrial fibrillation?
Tieleman RG; Van Gelder IC; Bosker HA; Kingma T; Wilde AA; Kirchhof CJ; Bennekers JH; Bracke FA; Veeger NJ; Haaksma J; Allessie MA; Crijns HJ
Heart Rhythm; 2005 Mar; 2(3):223-30. PubMed ID: 15851308
[TBL] [Abstract][Full Text] [Related]
51. Efficacy and safety of transvenous atrial cardioversion in patients with mitral valve disease and long-standing atrial fibrillation.
Grönefeld GC; Li YG; Bogun F; Hohnloser SH
Pacing Clin Electrophysiol; 2000 Nov; 23(11 Pt 2):1894-7. PubMed ID: 11139952
[TBL] [Abstract][Full Text] [Related]
52. Clinical study of the acute effects of intravenous nifekalant on the defibrillation threshold in patients with persistent and paroxysmal atrial fibrillation.
Okishige K; Uehara H; Miyagi N; Nakamura K; Azegami K; Wakimoto H; Ohba K; Hirao K; Shimabukuro M; Isobe M
Circ J; 2008 Jan; 72(1):76-80. PubMed ID: 18159104
[TBL] [Abstract][Full Text] [Related]
53. Waveform optimization for internal cardioversion of atrial fibrillation.
Kodoth V; Castro NC; Glover BM; Anderson JM; Escalona OJ; Lau E; Manoharan G
J Electrocardiol; 2011; 44(6):689-93. PubMed ID: 22018484
[TBL] [Abstract][Full Text] [Related]
54. Efficacy and tolerability of transvenous low energy cardioversion of paroxysmal atrial fibrillation in humans.
Murgatroyd FD; Slade AK; Sopher SM; Rowland E; Ward DE; Camm AJ
J Am Coll Cardiol; 1995 May; 25(6):1347-53. PubMed ID: 7722132
[TBL] [Abstract][Full Text] [Related]
55. [Ventricular fibrillation in intra-atrial cardioversion of atrial fibrillation].
Kettering K; Mewis C; Riemer M; Kühlkamp V
Z Kardiol; 2000 Apr; 89(4):269-73. PubMed ID: 10867999
[TBL] [Abstract][Full Text] [Related]
56. Rapid atrial pacing does not decrease the atrial defibrillation threshold.
Frykman V; Darpo B; Ayers GM; Bergfeldt L; Linde C; Rosenqvist M
Pacing Clin Electrophysiol; 2003 Jul; 26(7 Pt 1):1461-6. PubMed ID: 12914622
[TBL] [Abstract][Full Text] [Related]
57. Multicenter low energy transvenous atrial defibrillation (XAD) trial results in different subsets of atrial fibrillation.
Lévy S; Ricard P; Lau CP; Lok NS; Camm AJ; Murgatroyd FD; Jordaens LJ; Kappenberger LJ; Brugada P; Ripley KL
J Am Coll Cardiol; 1997 Mar; 29(4):750-5. PubMed ID: 9091520
[TBL] [Abstract][Full Text] [Related]
58. Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter.
Van Gelder IC; Crijns HJ; Van Gilst WH; Van Wijk LM; Hamer HP; Lie KI
Am J Cardiol; 1989 Dec; 64(19):1317-21. PubMed ID: 2511744
[TBL] [Abstract][Full Text] [Related]
59. Evaluation of the defibrillation threshold in atrial fibrillation by transoesophageal cardioversion using a biphasic impulse.
Prochaczek F; Winiarska H; Kończakowski P; Pyka R; Dziuk D; Gałecka J
Kardiol Pol; 2006 Apr; 64(4):373-9; discussion 380-2. PubMed ID: 16699980
[TBL] [Abstract][Full Text] [Related]
60. Nonlinear analysis of the ECG during atrial fibrillation in patients for low energy internal cardioversion.
Diaz J; Gonzalez C; Escalona O; Glover BM; Manoharan G
Annu Int Conf IEEE Eng Med Biol Soc; 2008; 2008():1619-22. PubMed ID: 19162986
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
